HomeLatest NewsCovid-19Joint CDC and FDA Statement on J&J Covid Vaccine

Joint CDC and FDA Statement on J&J Covid Vaccine

U.S. Department of Health & Human Services (HHS) released a joint statement from the Centers of Disease Control (CDC) and Federal Drug Administration (FDA) on the Johnson & Johnson COVID-19 Vaccine. Based on six reported cases of a rare and severe type of blood clot, HHS recommends that vaccine providers pause on administering the Johnson & Johnson (J&J) COVID-19 vaccine.

The CDC’s Advisory Committee on Immunization Practices (ACIP) is meeting April 14 and will provide updates. The CDC and FDA will provide additional information and answer questions at a media briefing. A recording of that media call will be available on the FDA’s YouTube channel.

People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System.

Stay Connected

Unified Voice Newsletter

Events This Month

May

30may11:00 am12:00 pmEmployee Accountability: How to Address Problem Behaviors and AttitudesSDAHO Webinar

30may11:00 am12:00 pmExploring an Evidence-based Toolkit and Tailoring Messages to Specific Audiences

30may11:30 am12:30 pmSerious Illness DiscussionMJHS Hospice and Palliative Care Webinar

30may12:00 pm1:00 pmOverview of Proposed IPPS Rule (FY) 2025AHA Webinar

31may9:00 am3:00 pmEmpowerED Leadership ConferenceSDAHEC Conference


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact